Avoid common mistakes on your manuscript.
Earlier, the personalised “3S” paradigm of preclinical anti-cancer drug testing was developed in parallel with a new conception of predictive, preventive, and personalised medicine. The paradigm includes three main points: 1) S et of complementary mouse models to reproduce a wide range of human breast cancer (BC) types; 2) S teps of preclinical anti-cancer drug testing procedure starting from in vitro and in vivo research on transplanted and spontaneous BC mouse models followed by probing of preventive regimen(s); (3) S tratified sampling as a methodology to distinguish more homogeneous subgroups within a heterogeneous population of experimental inbred mice using maximal number of individual recipient characteristics before and after testing procedure. This personalised procedure permits revealing of both positive and negative effects of a given drug.
Two types of different mouse models for preventive regimen testing exist within our paradigm; while commonly used preclinical drug testing procedures rarely include preventive regimen tests as one-level transplanted models are generally accepted. In contrast, our multistage conception proposes both transplanted and spontaneous BC mouse models using. The key advantage of a transplantable model is simultaneous developing of several homogenous populations of tumour-bearing mice. However, this mouse model preserves well-known limitations as healthy young recipient mice do not reflect numerous main characteristics of cancer patients that are mostly aged having a number of concomitant chronic inflammatory diseases. Furthermore, autochthonous carcinogenesis in humans and mice is a multi-staged process that is characterised as gradual transformation of cells and evolutionary expansion of cell populations in situ; and immune system is supposed to play a key role in this process. Earlier, we showed that our non-SPF conventional mouse strains with high frequency of spontaneous BC in aged females with preceded inflammatory diseases mimic the human BC aetiology/morphology properly. Several studies of preventive regimen tests in both transplanted and pre-cancerous spontaneous models are presented here to illustrate the acceptability of our paradigm. Firstly, a number of prestart transplanted mouse models of BC were used to test preventive regimens of immunotherapy by interleukin-2 and Imunofan®. In majority of our experiments, a single application of immunostimulants 3 days before tumour cell inoculation resulted in significant stimulation of tumour appearance in treated male recipients. In parallel, pre-cancerous BLRB and CBRB aged females were used as spontaneous models to test preventive regimens of the same immunostimulants. In contrast with above-mentioned data, clear age-related inhibition of BC appearance in pre-cancerous treated groups was observed. Transplanted mouse models hardly may be considered as an adequate model to test preventive regimens of immunotherapy against BC; but this test is suggested to compare extent of efficacy of various immunostimulants. While prophylactic anti-cancer effect of used drugs was revealed in aged pre-cancerous females, obtained contradictory data warn against uncontrolled usage of immunostimulants in breast cancer prone population. In summary, our original anti-cancer drug methodology demonstrates practical and scientific applicability.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Moiseeva, E. Preventive regimen of immunostimulants within personalised “3S” paradigm of anticancer drug testing. EPMA Journal 5 (Suppl 1), A35 (2014). https://doi.org/10.1186/1878-5085-5-S1-A35
Published:
DOI: https://doi.org/10.1186/1878-5085-5-S1-A35